Transcriptional regulation of a BMP-6 promoter by estrogen receptor α

Journal of Bone and Mineral Research

Volumn 19, Issue 3, 2004, Pages 447-454

  Ong, Delia B ^a   Colley, Shane M ^a   Norman, Michael R ^a   Kitazawa, Sohei ^b   Tobias, Jonathan H ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b KOBE UNIVERSITY   (Japan)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antiestrogens; Bone morphogenetic protein 6; Estrogen receptor; Osteoblasts

Indexed keywords

16ALPHA HYDROXYESTRONE; 4 HYDROXYTAMOXIFEN; ANDROSTANOLONE; BONE MORPHOGENETIC PROTEIN 6; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GENISTEIN; RALOXIFENE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG SPECIFICITY; GENETIC TRANSFECTION; HEPATOMA CELL; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; NONHUMAN; OSTEOBLAST; PROMOTER REGION; PROTEIN ANALYSIS; RAT; TRANSCRIPTION REGULATION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; OSTEOGENESIS; PROMOTER REGIONS (GENETICS); RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 2942744899     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.0301249     Document Type: Article

References (35)

1. Turner RT, Wakley GK, Hannon KS, Bell NH 1987 Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 2:449-456.
2. Evans G, Bryant HU, Magee D, Sato M, Turner RT 1994 The effects of raloxifene on tibia histomorphometry in ovariectomised rats. Endocrinology 134:2283-2288.
3. Jimenez MA, Maghee DE, Bryant HU, Turner RT 1997 Clomiphene prevents cancellous bone loss from the tibia of ovariectomised rats. Endocrinology 138:1794-1800.
4. Sibonga JD, Dobnig H, Harden RM, Turner RT 1998 Effect of the high-affinity estrogen receptor ligand ICI 182, 780 on the rat tibia. Endocrinology 139:3736-3742.
5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637-645.
6. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C-Y, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 96:3999-4004.
7. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508-1510.
8. Yang NN, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273:1222-1225.
9. van den Wijngaard A, Mulder WR, Dijkema R, Boersma CJ, Mosselman S, van Zoelen EJ, Olijve W 2000 Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Mol Endocrinol 14:623-633.
10. Yamaguchi A, Komori T, Suda T 2000 Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs and Cbfa1. Endocr Rev 21:393-411.
11. Bord S, Beavan S, Ireland D, Horner A, Compston JE 2001 Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: Role of locally produced growth factors. Bone 29:216-222.
12. McDougall KE, Perry MJ, Gibson RL, Colley SM, Korach KS, Tobias JH 2003 ERalpha-dependency of estrogen's stimulatory action on cancellous bone formation in male mice. Endocrinology 144:1994-1999.
13. McDougall KE, Perry MJ, Gibson R, Bright J, Colley S, Hodgin JB, Smithies O, Tobias JH 2002 Estrogen-induced osteogenesis in intact female mice lacking ERbeta. Am J Physiol 283:E817-E823.
14. Plant A, Tobias JH 2002 Increased bone morphogenetic protein 6 expression in mouse long bones following estrogen administration. J Bone Miner Res 17:782-790.
15. McDougall KE, Perry MJ, Whitworth T, Robertson EJ, Tobias JH 2002 Impaired osteogenic response of Bmp6 null mice. J Bone Miner Res 17:S1;S143.
16. Hall JM, McDonnell DP 1999 The estrogen receptor beta isoform (ERB) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566-5578.
17. Tamada H, Kitazawa R, Gohji K, Kamidono S, Maeda S, Kitazawa S 1998 Molecular cloning and analysis of the 5′-flanking region of the human morphogenetic protein-6. Biochim Biophys Acta 1395: 247-251.
18. Htun H, Holth LT, Walker D, Davie JR, Hager GL 1999 Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 10:471-486.
19. Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304.
20. Vyhlidal C, Li X, Safe S 2002 Estrogen regulation of transferrin gene expression in MCF-7 human breast cancer cells. J Mol Endocrinol 29:305-317.
21. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468.
22. Clement JH, Sanger J, Hoffken K 1999 Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80:250-256.
23. Tamada H, Kitazawa R, Gohji K, Kitazawa S 2001 Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. J Bone Miner Res 16:487-496.
24. Maki DD, Grossman RI 2000 Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 21:1064-1066.
25. Tou L, Quibria N, Alexander JM 2001 Regulation of human cbfa1 gene transcription in osteoblasts by selective estrogen receptor modulators (SERMs). Mol Cell Endocrinol 183:71-79.
26. Tobias JH 1999 The effects of SERMs on the skeleton. J Endocrinol Invest 22:604-608.
27. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30.
28. Dauvois S, White R, Parker MG 1992 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388.
29. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730.
30. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846.
31. Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL 1998 Bone morphogenetic protein-6 production in human osteoblast cell lines. J Clin Invest 101:413-422.
32. Levine M, Tjian R 2003 Transcription regulation and animal diversity. Nature 424:147-151.
33. Sutherland MK, Hui DU, Rao LG, Wylie JN, Murray TM 1996 Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells: Association of receptor levels with alkaline phosphatase activity. Bone 18:361-369.
34. Lambertini E, Penolazzi L, Aguiari G, del Senno L, Pezzetti F, Sollazzo V, Piva R 2002 Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor alpha gene. Biochem Biophys Res Commun 292:761-770.
35. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T 1997 Expression of estrogen receptor beta in rat bone. Endocrinology 138:4509-4512.